

FIRST-NAMED INVENTOR: Tobin

58  
59. A pharmaceutical composition comprising the composition of claim 58 and a pharmaceutically acceptable carrier.--

### REMARKS

Upon entry of the amendment claim 18, and claims 39-59 will be pending in the application. Claims 1-17 and 19-37 are cancelled as drawn to non-elected subject matter. Support for the amendment to claim 18 and for new claims 39-59 appears in, e.g., original claim 13 and at page 23, lines 1-22 of the specification. No new matter has been added. An appendix illustrates the amendments to the specification.

The application is believed in condition for allowance, and such action is respectfully requested. The Commissioner is authorized to charge any fees that may be due, or credit any overpayments of same, to Deposit Account No. 50-0311, Ref. No. 22058-516 DIV CON.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,829  
David E. Johnson, Reg. No. 41,874  
Attorney for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: December 27, 2002

FIRST-NAMED INVENTOR: Tobin

## Appendix

18. (Amended) A composition comprising an antibody which specifically reacts with a human IL-11R protein [of claim 13].

TRA 1747672v1